JP2024501658A - 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 - Google Patents

多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 Download PDF

Info

Publication number
JP2024501658A
JP2024501658A JP2023537923A JP2023537923A JP2024501658A JP 2024501658 A JP2024501658 A JP 2024501658A JP 2023537923 A JP2023537923 A JP 2023537923A JP 2023537923 A JP2023537923 A JP 2023537923A JP 2024501658 A JP2024501658 A JP 2024501658A
Authority
JP
Japan
Prior art keywords
inhibitor
alkyl
flt3
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501658A5 (https=
Inventor
ホイット，スコット，ブライアン
トーマス，クレイグ，ジョセフ
スターチナウスキー，ダニエル，ティー．
ローゼンバウム，ジャン，スーザン
マルドナド，ガブリエル グラシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children S Hospital Medical Center
Original Assignee
Children S Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children S Hospital Medical Center filed Critical Children S Hospital Medical Center
Publication of JP2024501658A publication Critical patent/JP2024501658A/ja
Publication of JP2024501658A5 publication Critical patent/JP2024501658A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023537923A 2020-12-23 2021-12-23 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 Pending JP2024501658A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063129895P 2020-12-23 2020-12-23
US63/129,895 2020-12-23
PCT/US2021/065037 WO2022140647A1 (en) 2020-12-23 2021-12-23 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2024501658A true JP2024501658A (ja) 2024-01-15
JP2024501658A5 JP2024501658A5 (https=) 2025-01-07

Family

ID=82158501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537923A Pending JP2024501658A (ja) 2020-12-23 2021-12-23 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用

Country Status (9)

Country Link
US (1) US12612410B2 (https=)
EP (1) EP4267142A4 (https=)
JP (1) JP2024501658A (https=)
CN (1) CN117015380A (https=)
AU (1) AU2021410783A1 (https=)
CA (1) CA3201841A1 (https=)
IL (1) IL303887A (https=)
MX (1) MX2023006938A (https=)
WO (1) WO2022140647A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250431A2 (en) * 2022-06-22 2023-12-28 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507032A (ja) * 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
JP2014508180A (ja) * 2011-03-17 2014-04-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イミダゾピラジン
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20200270242A1 (en) * 2016-08-17 2020-08-27 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1014572B8 (pt) * 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2014210255A1 (en) 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
US11542261B2 (en) * 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
DK3500571T3 (da) * 2016-08-17 2021-03-08 Childrens Hospital Med Ct Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf
TW201822764A (zh) * 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
WO2019002606A1 (en) * 2017-06-30 2019-01-03 Selvita S.A. ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507032A (ja) * 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
JP2014508180A (ja) * 2011-03-17 2014-04-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イミダゾピラジン
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20200270242A1 (en) * 2016-08-17 2020-08-27 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Quantitative structure-activity relationship (QSAR) study of interleukin-1 receptor associated kinas", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 25, no. 6, JPN6025030386, 2010, pages 844 - 853, ISSN: 0005651854 *

Also Published As

Publication number Publication date
CN117015380A (zh) 2023-11-07
AU2021410783A9 (en) 2024-10-17
IL303887A (en) 2023-08-01
MX2023006938A (es) 2023-10-13
US20240294530A1 (en) 2024-09-05
US12612410B2 (en) 2026-04-28
AU2021410783A1 (en) 2023-08-10
EP4267142A1 (en) 2023-11-01
CA3201841A1 (en) 2022-06-30
WO2022140647A1 (en) 2022-06-30
EP4267142A4 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
US12534469B2 (en) Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof
JP2023538242A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
US20250154144A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
TW202415655A (zh) １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑
US12612410B2 (en) Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof
US20250368648A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023150601A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
JP2025525325A (ja) キノロンｂｃｌ６二官能性分解剤
JP2026506363A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用
EP4598539A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023250431A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
HK40101779A (zh) 多环irak和flt3抑制化合物以及其用途
CN118613480A (zh) 多环irak和flt3抑制化合物以及其用途
WO2025137567A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324